Bcl-2 modulation to activate apoptosis in prostate cancer

Molecular Cancer Research

Volumn 7, Issue 9, 2009, Pages 1487-1496

  Bray, Kevin ^a,b   Chen, Hsin Yi ^a,b   Karp, Cristina M ^a   May, Michael ^a   Ganesan, Shridar ^a,c   Karantza Wadsworth, Vassiliki ^a,c   DiPaola, Robert S ^a,c   White, Eileen ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CISPLATIN; ETOPOSIDE; PACLITAXEL; PROTEIN BCL 2; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL HYPOXIA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; EXPLANT; GENE CONTROL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT OUTCOME; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; CISPLATIN; DRUG SYNERGISM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NITROPHENOLS; PACLITAXEL; PIPERAZINES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 70349490638     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0166     Document Type: Article

References (50)

1. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. World J Urol 2005;23:10-13
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
3. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-885 (Pubitemid 41746032)
4. Karantza-Wadsworth V, White E. Programmed cell death. Cancer: principles and practice of oncology. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. 8th ed. Baltimore: Lippincott, Williams, & Wilkins; 2008. p. 93-101.
5. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007;19:488-496 (Pubitemid 47487452)
6. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004;305:626-629
7. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-219 (Pubitemid 38167313)
8. Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005;19:1263-1268 (Pubitemid 41003016)
9. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944 (Pubitemid 23006303)
10. DiPaola RS, Rafi MM, Vyas V, et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 1999;17:2213-2218 (Pubitemid 29318855)
11. Morris MJ, Cordon-Cardo C, Kelly WK, et al. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol 2005;13:6-13. (Pubitemid 40283796)
12. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-683
13. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-185 (Pubitemid 47199122)
14. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388 (Pubitemid 44693472)
15. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681 (Pubitemid 40825512)
16. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-1183 (Pubitemid 46270776)
17. Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 2003;17:2922-2932 (Pubitemid 37523156)
18. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003;17:1475-1486 (Pubitemid 36734705)
19. Yang C, Kaushal V, Shah SV, Kaushal GP. Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007;292:F1710-7.
20. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-238 (Pubitemid 40568682)
21. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576 (Pubitemid 26135897)
22. Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin 1989;39:376-393
23. Degenhardt K, White E. A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin Cancer Res 2006;12:5298-5304 (Pubitemid 44497242)
24. Mathew R, Degenhardt K, Haramaty L, Karp CM, White E. Chapter 5 immortalized mouse epithelial cell models to study the role of apoptosis in cancer. Methods Enzymol 2008;446:77-106.
25. Karp CM, Tan TT, Mathew R, et al. Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression. Cancer Res 2008;68:4105-4115
26. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992;52:5991-5996
27. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990;50:6830-6832
28. Watanabe M, Shiraishi T, Yatani R, Nomura AM, Stemmermann GN. International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer 1994;58:174-178 (Pubitemid 24240091)
29. Rijnders AW, van der Korput JA, van Steenbrugge GJ, Romijn JC, Trapman J. Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 1985;132:548-554 (Pubitemid 16198660)
30. Karantza-Wadsworth V, Patel S, Kravchuk O, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007;21:1621-1635 (Pubitemid 47026367)
31. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-1738 (Pubitemid 129515880)
32. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-365 (Pubitemid 43668734)
33. Bouillet P, Cory S, Zhang LC, Strasser A, Adams JM. Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell 2001;1:645-653 (Pubitemid 33586117)
34. Bruckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 2000;19:5251-5258
35. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403. (Pubitemid 40193310)
36. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791 (Pubitemid 46192219)
37. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399
38. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-1305 (Pubitemid 41003019)
39. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428
40. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-1186
41. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943-951 (Pubitemid 46655455)
42. Witham J, Valenti MR, De-Haven-Brandon AK, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007;13:7191-7198 (Pubitemid 350276906)
43. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006;103:14907-14912 (Pubitemid 44527827)
44. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-836
45. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived - but they can be improved. Cancer Biol Ther 2003;2:S134-9.
46. Takimoto CH. Why drugs fail: of mice and men revisited. Clin Cancer Res 2001;7:229-230
47. Degenhardt K, Chen G, Lindsten T, White E. BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell 2002;2:193-203. (Pubitemid 41043975)
48. Kasof GM, Goyal L, White E. Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol 1999;19:4390-4404 (Pubitemid 29242013)
49. Degenhardt K, Sundararajan R, Lindsten T, Thompson C, White E. Bax and Bak independently promote cytochrome C release from mitochondria. J Biol Chem 2002;277:14127-14134 (Pubitemid 34968024)
50. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004;18:2095-2107 (Pubitemid 39166627)